DOPPS Program Area, Arbor Research Collaborative for Health, Ann Arbor, Michigan.
School of Medicine, Pontifícia Universidade Católica do Paraná, Curitiba, Brazil.
Kidney360. 2020 Jul 1;1(8):855-862. doi: 10.34067/KID.0001442020. eCollection 2020 Aug 27.
In nondialysis CKD (ND-CKD), anemia is a multifactorial and complex condition in which several dysfunctions dynamically contribute to a reduction in circulating hemoglobin (Hb) levels in red blood cells. Anemia is common in CKD and represents an important and modifiable risk factor for poor clinical outcomes. Importantly, symptoms related to anemia, including reduced physical functioning and fatigue, have been identified as high priorities by patients with CKD. The current management of anemia in ND-CKD (., parameters to initiate treatment, Hb and iron indexes targets, choice of therapies, and effect of treatment on clinical and patient-reported outcomes) remains controversial. In this review article, we explore the epidemiology of anemia in ND-CKD and revise current recommendations and controversies in its management. Exploring data from real-world clinical practices, particularly from the Chronic Kidney Disease Outcomes and Practice Patterns Study (CKDopps), we highlight the current challenges to translating current recommendations to clinical practice, providing patients' perspectives of anemia and how it affects their quality of life. Finally, we summarize recent advances in the field of anemia that may change the way this condition will be managed in the future.
在非透析慢性肾脏病(ND-CKD)中,贫血是一种多因素和复杂的病症,其中几种功能障碍会动态地导致循环血液中红细胞内血红蛋白(Hb)水平降低。贫血在 CKD 中很常见,是不良临床结局的一个重要且可改变的危险因素。重要的是,与贫血相关的症状,包括体力活动减少和疲劳,已被 CKD 患者确定为高度优先事项。目前 ND-CKD 贫血的管理(即,开始治疗的参数、Hb 和铁指标目标、治疗方法的选择以及治疗对临床和患者报告结局的影响)仍然存在争议。在这篇综述文章中,我们探讨了 ND-CKD 中贫血的流行病学,并修订了目前关于其管理的建议和争议。我们从真实世界的临床实践中探索数据,特别是从慢性肾脏病结局和实践模式研究(CKDopps)中,强调了将当前建议转化为临床实践的当前挑战,提供了患者对贫血的看法以及贫血如何影响他们的生活质量。最后,我们总结了贫血领域的最新进展,这些进展可能会改变未来对这种疾病的管理方式。